Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Celldex Therapeutics Inc CLDX

Healthcare Biotechnology
Celldex Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on exploring the science of mast cell biology and the development of transformative therapeutics for patients. Its drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases for which available treatments are inadequate. Its Barzolvolimab, a monoclonal antibody... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:CLDX)

Celldex Therapeutics Presents Landmark 52 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EADV 2024

GlobeNewswire 4 days ago

Celldex Announces Upcoming Late Breaking Oral Presentation of 52 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EADV Congress 2024

GlobeNewswire 13 days ago

Celldex Therapeutics to Present at Upcoming Investor Conferences

GlobeNewswire September 12, 2024

Celldex Reports Second Quarter 2024 Financial Results and Provides Corporate Update

GlobeNewswire August 8, 2024

Celldex Therapeutics Presents Positive Topline Results from Barzolvolimab Phase 2 Study in Chronic Inducible Urticaria

GlobeNewswire July 29, 2024

Celldex Therapeutics Initiates Global Phase 3 Program for Barzolvolimab in Patients with Chronic Spontaneous Urticaria

GlobeNewswire July 16, 2024

Celldex Therapeutics to Present at Jefferies Healthcare Conference

GlobeNewswire June 4, 2024

Celldex Therapeutics Presents Data Demonstrating Profound Improvements in Angioedema in Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI 2024

GlobeNewswire June 2, 2024

Celldex Announces First Patient Dosed in Phase 2 Study of Barzolvolimab in Prurigo Nodularis

GlobeNewswire May 15, 2024
View More News ››

Opinion & Analysis (NDAQ:CLDX)

Investing in biotech stocks is not for amateurs (CLDX) (NPSP)

Marc Lichtenfeld January 17, 2014

Big money to be made in biotech stocks

Andrew Mickey December 1, 2008

Dividend and speculative stock picks

J.W. Cotton October 28, 2008
View More Opinion ››

Bullboard Posts (NDAQ:CLDX)

Woo-ho

Finally, a rally, a trend change, and the company coming back to life...!
paths - June 17, 2020

it's a sell today for me

at.$3.27 per share,it's been over a year for me with this one and it's time to take my profits out.
coolfooldumbguy - February 21, 2020

this stock

should do well this year for me,so glta shareholders buying it at these low prices.
coolfooldumbguy - February 18, 2019

forming a head & shoulders pattern

which is a really good chart for this one,so glta.
coolfooldumbguy - February 6, 2019

climb up starts today for me

so glta shareholders.
coolfooldumbguy - January 2, 2019

added more of this one

at these low prices,averaging my costs down,so glta.
coolfooldumbguy - December 7, 2018
View more Bullboard ››

Copper Lake Resources Ltd.

Copper Lake Resources Ltd.

Copper Lake Resources Ltd. is a Canadian mineral exploration and development company with interests in two projects both ...
View More »